Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization

Journal of Molecular Diagnostics

Volumn 14, Issue 4, 2012, Pages 322-327

  Braun, Martin ^a   Stomper, Julia ^a   Boehm, Diana ^a   Vogel, Wenzel ^a   Scheble, Veit J ^b   Wernert, Nicolas ^a   Adler, David ^a   Fend, Falko ^b   Kristiansen, Glen ^a   Perner, Sven ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ACCURACY; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DUAL COLOR CHROMOGENIC IN SITU HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INSERTION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; SILVER IN SITU HYBRIDIZATION;

EID: 84862705980     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2012.01.017     Document Type: Article

References (32)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648
2. Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F, Perner S: Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011, 58:1028-1036
3. Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C: ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 2010, 23:1499-1506
4. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, Osunkoya AO, Maclennan GT, Montironi R, Cheng L: ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin, Mod Pathol 2011, 24:1120-1127
5. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ: ERG gene rearrangements are common in prostatic small cell carcinomas, Mod Pathol 2011, 24:820-828
6. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB: Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009, 22:1176-1185
7. Scheble VJ, Braun M, Wilbertz T, Stiedl AC, Petersen K, Schilling D, Reischl M, Seitz G, Fend F, Kristiansen G, Perner S: ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010, 56:937-943
8. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA: ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009, 56:275-286
9. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S: ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010, 23:1061-1067
10. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA: TMPRSS2: ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Res 2006, 66:8337-8341
11. Wang J, Cai Y, Ren C, Ittmann M: Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006, 66:8347-8351
12. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM: Noninvasive detection of TMPRSS2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006, 8:885-888
13. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA: Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007, 13:5103-5108
14. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA: Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598
15. van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J: Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011, 24:1128-1138
16. He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M: The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol 2011, 35:608-614
17. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000, 157:1467-1472
18. Dandachi N, Dietze O, Hauser-Kronberger C: Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002, 82:1007-1014
19. Sholl LM, John Iafrate A, Chou YP, Wu MT, Goan YG, Su L, Huang YT, Christiani DC, Chirieac LR: Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 2007, 20:1028-1035
20. Bartlett JM, Campbell FM, Ibrahim M, Wencyk P, Ellis I, Kay E, Connolly Y, O'Grady A, Di Palma S, Starczynski J, Morgan JM, Jasani B, Miller K: Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol 2009, 132:514-520
21. Bartlett JM, Campbell FM, Ibrahim M, O'Grady A, Kay E, Faulkes C, Collins N, Starczynski J, Morgan JM, Jasani B, Miller K: A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol 2011, 135:157-162
22. Hainfeld JF, Eisen RN, Tubbs RR, Powell RD: Enzymatic metallography: a simple new staining method. In: Lyman CE, Albrecht RM, Carter CB, Dravid VP, Herman B, Schatten H, editors. Microsc Microanal, 8 (Suppl. 2: Proceedings) 2002, 916 CD
23. Hainfeld J, Powell R, Hacker G: Nanoparticle molecular labels. Nanobiotechnology. Edited by Mirkin CA, Niemeyer CM. Weinheim, Germany, Wiley-VCH, 2004, pp 353-386
24. Tubbs R, Pettay J, Hicks D, Skacel M, Powell R, Grogan T, Hainfeld J: Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol 2004, 35:589-594
25. Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF, Tubbs RR: Metallographic in situ hybridization. Hum Pathol 2007, 38:1145-1159
26. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM: Characterization of TMPRSS2- ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008, 68:3584-3590
27. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS: Characterization of ERG. AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69:2912-2918
28. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA: ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2009, 75:762-767
29. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA: TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007, 31:882-888
30. Gaiser T, Waha A, Moessler F, Bruckner T, Pietsch T, von Deimling A: Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. Mod Pathol 2009, 22:1263-1271
31. Fritzsche FR, Bode PK, Moch H, Kristiansen G, Varga Z, Bode B: Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). Am J Surg Pathol 2010, 34:1180-1185
32. Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, Morey A, Bilous M, Nagle R, Prescott N, Wang L, Dragovich L, McElhinny A, Garcia CF, Ranger-Moore J, Free H, Powell W, Loftus M, Pettay J, Gaire F, Roberts C, Dietel M, Roche P, Grogan T, Tubbs R: Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010, 34:767-776